Possible Drug Target to Reduce Allergic Reactions

by Julia Samuel on February 26, 2018 at 5:34 PM
Possible Drug Target to Reduce Allergic Reactions

Not one but several proteins can interact in blood vessels and cause a severe allergic reaction known as anaphylaxis.

Prospects for inhibiting the most dangerous symptoms of allergic reactions may be brighter with the publication of a new study that identifies a possible target for drug therapies.


Research conducted at Cincinnati Children's Hospital Medical Center and published in the†Journal of Allergy and Clinical Immunology†found that several proteins can interact in blood vessels to intensify the respiratory and circulatory symptoms of a severe allergic reaction known as anaphylaxis. Pharmaceuticals that target these proteins, including a drug approved to treat a chronic skin condition, may be able to moderate reactions and make anaphylaxis less deadly.

An allergic reaction occurs when the immune system recognizes an otherwise harmless protein (the allergen) as an invading threat, setting off a chain of events that lead to disease symptoms. The new findings center on the vascular epithelium (VE) cells that line the inner surfaces of blood vessels. Neighboring VE cells form a barrier that prevents fluid loss. During severe anaphylaxis, disrupting the VE barrier allows fluid to leak from the blood vessels into surrounding tissues, which can lead to shock, respiratory failure, and death.

"These studies show that we need to think beyond the immune cells with respect to food allergy as it is becoming increasingly clear that non-immune cells can also influence anaphylaxis," explained the principal investigator, Dr. Simon Hogan.

Therapies to prevent the life-threatening symptoms of anaphylaxis could transform the lives of 15 million Americans with food allergies. The studies received support from Food Allergy Research & Education (FARE), the world's largest private source of funding for food allergy research, which granted Hogan a multi-year award in 2015.

"For most individuals with food allergies, a top research priority is the development of therapies to control the severe symptoms that make food allergy reactions so unpredictable and dangerous," said Mary Jane Marchisotto, SVP of Research and International Operations at FARE.

Most allergy symptoms are triggered when a small molecule called histamine is released from white blood cells that normally promote healing and fight infection. Other molecules released by white blood cells during an allergic reaction include a small protein called interleukin 4 (IL-4). Researchers in the Hogan laboratory examined the interaction of these molecules and the IL-4 receptor protein on VE barrier function of blood vessels in anaphylaxis.

Studies revealed that anaphylaxis was linked with loss of VE barrier integrity in response to histamine. The authors showed that the histamine response is more severe in the presence of IL-4 signaling and that higher levels of IL-4 and histamine increased the loss of fluid from blood vessels to surrounding tissue and made anaphylaxis more severe.

The finding that increased fluid loss is dependent on the activity of the IL-4 receptor suggests that drugs targeting IL-4 receptor activity may be useful in limiting anaphylaxis symptoms. One such drug has already been approved for treating moderate to severe eczema.

Hogan envisions a possible role for this research in preventing severe reactions during allergen immunotherapy, in which repeated allergen exposure is used to make the patient's immune system less sensitive to the allergen.

Source: Eurekalert
Font : A-A+



Recommended Readings

Latest Research News

Does Twice Daily Stimulation Enhance Alzheimer's Mental Functions?
Electrical stimulation improves Alzheimer's patients' cognitive function and correlates with restored cortical plasticity.
South Korea's 2050 Forecast: Negative Growth Amid Low Fertility
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
New Immunotherapy for Psoriasis & Vitiligo
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
2050 Forecast: 1.06 Billion Individuals to Face 'Other' Musculoskeletal Disorders
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Gene Therapies Can Disrupt Gaucher Disease Drug Market
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Possible Drug Target to Reduce Allergic Reactions Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests